// App-Quantinova.ai

O21 : High sequential use of tumour necrosis factor inhibitors in a cohort of children and young people with juvenile idiopathic arthritis from the United Kingdom

Researchers

Presenter

  • Lianne Kearsley-Fleet

Principal Investigators

  • Eleanor Heaf

  • Rebecca Davies

  • Diederik De Cock

  • Eileen Baildam

  • Michael W Beresford

  • Helen E Foster

  • Taunton R Southwood

  • Wendy Thomson

  • Kimme L Hyrich

Medical Centers

  • Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom

  • Department of Endocrinology, Alder Hey Childrens NHS Foundation Trust, Liverpool, United Kingdom

  • Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

  • Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

  • Paediatric Immunology Department, Great North Childrens Hospital, Newcastle upon Tyne, United Kingdom,

  • Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom

  • Arthritis Research United Kingdom Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom

  • National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • TNF Receptor Superfamily Member 1B

Drug/Treatment

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved